Back to search results

Inspiratory Muscle Training for Heart Failure

This study is looking at how inspiratory muscle training (IMT) affects the breathing muscles during exercise in people with heart failure (HFpEF). IMT is a type of exercise that strengthens the muscles you use to breathe in. We want to see if this training changes how much blood flow your breathing muscles need. You might be able to join if you are at least 18 years old, have heart failure, and are currently taking SGLT2 inhibitors and spironolactone (and beta-blockers if you have high blood pressure). You should also have mild to moderate heart failure symptoms (NYHA I-III), a BMI of 40 or less, and be a non-smoker with a limited smoking history. The study plans to enroll 68 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 68 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurement is taken at baseline and again at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06510231

Inspiratory Muscle Training in HFpEF

Recruiting
NAAges 18+Interventional
Mayo Clinic
~68 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Inspiratory Muscle Training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in inspiratory muscle blood flow demand
Measured over Baseline, 8 weeks

Conditions

Heart Failure

Explore related trials

Heart Failure

NCT06510231

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joshua Smith, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Eric Bruhn, M.A.
[email protected]
507-266-2690
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 yrs of age
Receiving SGLT2 inhibitors and spironolactone (and beta-blocker use for HFpEF patients with hypertension) for \>3 months
NYHA symptoms I-III
Body mass index ≤40 kg/m2
Currently non-smokers with \<20 pack year history
Able to exercise (i.e. without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise)

Exclusion

Sustained ventricular tachycardia and/or ventricular fibrillation within 21 days of visit 1
Second or third degree heart block
Body mass index \>40 kg/m2
Current smokers and/or smoking history \>20 pack years
Pregnant women (testing will be done by research team if requested)
Glomerular filtration rate of \<30 mL/min/1.73m2 (initial screen via clinical record within the past 6 months and this will be assessed on Visit 1)
Individuals who are not able to engage in exercise
Uremia, history of allergy to iodides
Peripheral artery disease
Alanine transaminase and/or aspartate transaminase greater than 2 times the upper limit of normal (via clinical record within the past 6 months)
Asthmatic patients with a low symptom perception and suffer frequency, severe exacerbations or with an abnormally low perception of dyspnea
Ruptured eardrum or any other condition of the ear
History of spontaneous pneumothorax or osteoporosis with a history of rib fractures
History of lidocaine allergy.

What this trial measures

  • Change in inspiratory muscle blood flow demandBaseline, 8 weeks

    Inspiratory muscle blood flow demand will be measured via indocyanine green dye venous bolus injection. This will be measured in umol.